Editas Medicine Announces Third Quarter 2022 Results and Business Updates

November 2, 2022

https://www.globenewswire.com/news-release/2022/11/02/2546268/0/en/Editas-Medicine-Announces-Third-Quarter-2022-Results-and-Business-Updates.html

Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease

On track to announce initial preliminary clinical data from RUBY trial by year-end

Read more at globenewswire.com

Related news for (EDIT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.